Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-06-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于股票价格波动的风险提示性公告
Regulatory Filings Classification · 95% confidence The document is a risk warning announcement related to stock price volatility for Kunming Pharmaceutical Corporation (昆药集团股份有限公司). It includes details about recent stock price increases, company business and product information, and cautions investors about investment risks. It does not contain financial statements or detailed financial results, nor is it a report or presentation. It is a regulatory announcement aimed at informing investors about stock price risks and company status. The document length is short (1438 characters), and it is not a report publication announcement but a regulatory filing. Therefore, the best fitting category is Regulatory Filings (RNS).
2019-06-20 Chinese
关于《昆药集团关于股票交易异常波动有关事项的问询函》的回函
Regulatory Filings
2019-06-19 Chinese
关于公司股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Corporation regarding abnormal stock price fluctuations over three consecutive trading days. It includes details about the stock price movement, company operations, product sales proportions, ongoing drug development risks, and confirms no undisclosed material information exists. The document is a regulatory announcement about stock trading behavior and risk disclosure, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It fits the category of a Regulatory Filing (RNS) as it is a compliance disclosure related to stock trading rules and investor risk notification.
2019-06-19 Chinese
关于青蒿素类药品相关情况的说明公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Corporation regarding the status of its artemisinin-related products and the progress of a drug development project. It includes sales figures, project milestones, and risk disclosures related to clinical trials and regulatory approval. The document is relatively short (1070 characters) and does not contain detailed financial statements or comprehensive financial analysis. It is an informational announcement about product status and R&D progress rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a voting result, management change, or capital update. The content is primarily a risk disclosure and project update to investors. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2019-06-17 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Kunming Pharmaceutical Group Co., Ltd. It contains detailed provisions on company governance, shareholder rights, board structure, share issuance, share repurchase, and other corporate governance matters. It is a comprehensive governance document that sets out the internal rules and regulations of the company. There is no indication that this is an announcement or a summary; it is the full text of the company's Articles of Association. This type of document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2019-06-14 Chinese
九届十二次董事会决议
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the 12th meeting of the 9th board, including approval of amendments to the company bylaws and authorization related to a cooperation framework agreement. The content focuses on board decisions and management authorizations rather than financial results, audit opinions, or shareholder voting results. It is not a full annual or interim report, nor an earnings release or regulatory filing. The document fits best under Board/Management Information (MANG) as it announces board meeting resolutions and management authorizations.
2019-06-14 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.